WHOM is going to do the similar research on this for humans and stroke AND writeup a stroke protocol on it? With NO stroke leadership or strategy, NOTHING WILL BE DONE!
Nasal antibody spray heals stroke-related brain damage in animal models
- Delivery of therapeutics such as antibodies to the central nervous system is challenging due to the blood-brain barrier that prevents the entry of large molecules from circulation to the brain.
- Intranasal delivery bypasses the blood-brain barrier, and there is evidence to suggest that this noninvasive method can deliver detectable levels of antibodies to the brain.
- A new proof-of-concept study shows that intranasal delivery of antibodies against a protein that inhibits nerve fiber growth reached the brain in sufficient amounts to exert therapeutic effects in a rat model of stroke.
- These findings suggest that intranasal delivery may have promise for the delivery of therapeutic antibodies for not only stroke but also a vast array of neurological disorders, such as Alzheimer’s disease and multiple sclerosis.
Although the ability of intranasal administration to deliver small molecules to the brain has been established, only recent studies have shown that this mode of drug administration can also deliver larger molecules, such as antibodies, to the central nervous system (CNS).
However, it was unclear whether intranasal administration could deliver antibodies in sufficient quantities to the CNS to exert therapeutic effects.
A recent study published in PNAS now shows that the administration of antibodies against Nogo-A, a protein that inhibits nerve fiber growth, to a rat model of stroke via intranasal delivery was effective in reducing motor deficits associated with the stroke.
This functional recovery due to the administration of the therapeutic antibodies was accompanied by the compensatory growth of nerve fibers into the denervated regions of the spinal cord.
No comments:
Post a Comment